HomeCompareNYMT vs MRK

NYMT vs MRK: Dividend Comparison 2026

NYMT yields 11.25% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $35.7K in total portfolio value· pulled ahead in Year 2
10 years
NYMT
NYMT
● Live price
11.25%
Share price
$7.11
Annual div
$0.80
5Y div CAGR
-45.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.0K
Annual income
$2.81
Full NYMT calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — NYMT vs MRK

📍 MRK pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNYMTMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NYMT + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NYMT pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NYMT
Annual income on $10K today (after 15% tax)
$956.40/yr
After 10yr DRIP, annual income (after tax)
$2.39/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, MRK beats the other by $8,594.32/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NYMT + MRK for your $10,000?

NYMT: 50%MRK: 50%
100% MRK50/50100% NYMT
Portfolio after 10yr
$39.9K
Annual income
$5,058.29/yr
Blended yield
12.68%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

NYMT
Analyst Ratings
4
Buy
14
Hold
1
Sell
Consensus: Hold
Price Target
$11.25
+58.2% upside vs current
Range: $7.25 — $14.00
Altman Z
0.7
Piotroski
6/9
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NYMT buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNYMTMRK
Forward yield11.25%2.81%
Annual dividend / share$0.80$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-45.7%32.7%
Portfolio after 10y$22.0K$57.7K
Annual income after 10y$2.81$10,113.78
Total dividends collected$1.4K$29.8K
Payment frequencyquarterlyquarterly
SectorREITHealthcare
Analyst consensusHoldBuy
Analyst price target$11.25$128.54

Year-by-year: NYMT vs MRK ($10,000, DRIP)

YearNYMT PortfolioNYMT Income/yrMRK PortfolioMRK Income/yrGap
1$11,311$610.97$11,213$373.04+$98.00NYMT
2← crossover$12,453$350.70$12,667$512.06$214.00MRK
3$13,521$195.95$14,439$708.14$918.00MRK
4$14,576$107.96$16,640$988.16$2.1KMRK
5$15,655$59.06$19,432$1,394.07$3.8KMRK
6$16,783$32.19$23,057$1,992.90$6.3KMRK
7$17,975$17.51$27,889$2,894.79$9.9KMRK
8$19,243$9.52$34,518$4,286.29$15.3KMRK
9$20,595$5.17$43,912$6,494.35$23.3KMRK
10$22,040$2.81$57,714$10,113.78$35.7KMRK

NYMT vs MRK: Complete Analysis 2026

NYMTREIT

New York Mortgage Trust, Inc. acquires, invests in, finances, and manages mortgage-related single-family and multi-family residential assets in the United States. Its targeted investments include residential loans, second mortgages, and business purpose loans; structured multi-family property investments, such as preferred equity in, and mezzanine loans to owners of multi-family properties, as well as joint venture equity investments in multi-family properties; non-agency residential mortgage-backed securities (RMBS); agency RMBS; commercial mortgage-backed securities (CMBS); and other mortgage, residential housing, and credit-related assets. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was incorporated in 2003 and is headquartered in New York, New York.

Full NYMT Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this NYMT vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NYMT vs SCHDNYMT vs JEPINYMT vs ONYMT vs KONYMT vs MAINNYMT vs JNJNYMT vs ABBVNYMT vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.